Skip to main content

Table 1 Patient demographics and clinical characteristics at baseline

From: The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population

  Overall (n= 60) Insufficient response (n= 39) Insufficient tolerability (n= 21)
Gender, n (%)
 Male 37 (61.7) 22 (56.4) 15 (71.4)
 Female 23 (38.3) 17 (43.6) 6 (28.6)
Age, years (SD)c 38.0 (10.7) 40.5 (10.5)* 33.3 (9.9)*
Marital status, n (%)a
 Single 42 (70.0) 25 (64.1) 17 (81.0)
 Married 11 (18.3) 9 (23.1) 2 (9.5)
 Divorced 4 (6.7) 3 (7.7) 1 (4.8)
 Widowed 2 (3.3) 2 (5.1) 0 (0.0)
Employment status, n (%)a
 Employed 12 (20.0) 8 (20.5) 4 (19.0)
 Student/Retired 4 (6.7) 1 (2.6) 3 (14.3)
 Unemployed 43 (71.7) 30 (76.9) 13 (61.9)
Psychiatric history
 Disease duration, years (SD) 12.5 (9.3) 13.2 (9.6) 11.3 (8.8)
 Number of schizophrenic episodes over lifetime, n (SD) 3.6 (2.7) 3.2 (2.1) 4.3 (3.5)
 Presence of family members with schizophrenia, n (%) 9 (15.0) 4 (10.3) 5 (23.8)
Psychoactive medication at base, n (%)
 Any antipsychotics 59b (98.3) 38b (97.4) 21 (100.0)
  Risperidone 15 (25.0) 8 (20.5) 7 (33.3)
  Quetiapine IR 11 (18.3) 8 (20.5) 3 (14.3)
  Sulpiride 9 (15.0) 8 (20.5) 1 (4.8)
  Amisulpride 6 (10.0) 3 (7.7) 3 (14.3)
  Aripiprazole 5 (8.3) 3 (7.7) 2 (9.5)
  Olanzapine 5 (8.3) 3 (7.7) 2 (9.5)
  Ziprasidone 4 (6.7) 3 (7.7) 1 (4.8)
  Clozapine 3 (5.0) 1 (2.6) 2 (9.5)
Mean (SD) baseline scores
 PANSS 84.4 (17.7) 85.9 (17.5) 81.7 (18.2)
 CGI-S 4.7 (0.7) 4.7 (0.7) 4.7 (0.7)
  1. aOne patient with insufficient tolerance had no reported marital status and employment status.
  2. bOne patient with insufficient response had received no antipsychotics before entering the trial; Two patients did not report their previous antipsychotics.
  3. *p < .05, ct test = 2.595, p = .012